Ryan Mee, CEO of Fulcrum Metals, reviews FY23 and progress on the Gold Tailings Hub in Canada. Watch the video here.
Hmmmmm think there is a key point being missed here. Why would you go onto a share you haven’t got a position in and quite rightly as Baxter’s points out, put negative views, not just once but continuously. Put the shoe on the other foot, it is like me going onto the SNG board and state anto earlier comments ‘it has gone down so far (fact!), It's likely that it will go further down’ a) I have no investment in there so couldn’t care how the sp reacts. b) why in gods name would you want the SP to retract (obviously an ulterior motive c) I have better things to do with my time.
Indeed I am very much up for a balanced post and I do think it is important if you are invested or not, simply why take the amount of time to post on here if you are not invested?! Seems quite strange, but each to their own I suppose. It’s not a personal attack just a question really. All of your posts mention a downward trend?! Haven’t the whole of the bio pharm industry taken a hit over the last week due to that Pfizer announcement on the Covid play?! As you so eloquently mentioned, yes it has gone down, but has just as much ability to go back up. Look at the forthcoming news, to make it easier, refer to recent rns particularly around 301 MTA and full results on 201. Have a good weekend also.
a kicking on Phase II top line results. Having reviewed the RNS looks quite promising in all honesty, i think people are expecting far to much in an extremely regulated industry at this current time. Also, i don't understand why other posters come on an criticize Val and its products, for gods sake we are developing something in a very meaningful space to help sufferers. I look at other companies such as 4D and SCLP and genuinely want them to succeed and wouldn't for the life of me go on the board and be little them. ATB
With Keytruda ORR of 24% https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5574183/
Among the carnage from today, I see this post from besensible as extremely valuable. Researching the link provided - Response Rate as a Regulatory End Point in Single-Arm Studies of Advanced Solid Tumors https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5574183/ It notes within, although on NSCLC (which is 401 territory), explains the Objective Response Rate (ORR) very well. For Val 201 the ORR was established at 54% today on 12 patients. Interesting to read that pembrolizumab (Keytruda - Merck) only achieved ORR of 24% and has more severe side effects than found in Val 201 to date. Again interesting reading, tomorrow is another day. GL all :)
I can remember someone stating some time ago we had some interest from Shire Pharmaceuticals (I may have this way off track so please forgive me) on 201, for some reason or another it didn’t materialise. Do you think on the cusp of 201 results there could be some renewed interest from them? Also just found Shire are now owned by Takeda (Jap Pharma) could they possibly the comp that have the MTA on 301 also? Again, thinking out loud here. Hope Suze and the crew are prepping that RNS on 201 data, I find the RNSs now so much more informative with less questions being asked after. Great platform now to build from. ATB :)
And just to makes things easier please use this link - https://www.lse.co.uk/rns/VAL/
Absolute carnage on the stock markets this morning / early afternoon, however we are blue :) Agree with the comments, if the results were not as expected why would Suze expose herself like that? Should be tapping on 30s door alone on that update :)